ImmuCell Corp (ICCC) income statement
ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/303% above fair value
$11.25−0.08 (-0.71%)
Close on Nov 18, 2026Market cap $102.18MP/E 140.6Yield –
ImmuCell Corp income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 40.3%
- Operating margin
- 12.6%
- Net margin
- 2.6%
- Return on equity, FY2025
- -3.8%
Financial strength
- Current ratio
- 4.75
- Debt to equity
- 0.26
- Debt to assets
- 17.8%
- Cash to current liabilities
- 199.7%
Valuation
- P/E ratio
- 140.6
- Price to sales
- 3.33
- Price to book
- 3.26
- Dividend yield
- –
See a number that looks wrong?